REGISTERED USER
E-mail
Password
NEW USER REGISTRATION

Granulocyte/Monocyte Apheresis (GMA) is a non-pharmacological therapeutic alternative for the treatment of Inflammatory Bowel Disease (IBD), among other immune-mediated diseases. GMA has proven to be very effective and safe. Furthermore, it remains the only therapy targeting neutrophils, which are the hallmark of inflammatory bowel disease and, specifically, of Ulcerative Colitis (UC).

GMA has proven its efficacy in different clinical scenarios, especially when administered early. Unlike pharmacological treatments, it is extremely safe and has a unique, very low, profile of adverse effects, which makes it the ideal treatment for certain patient profiles, such as children and frail patients. When combined with biological therapy, GMA is an ideal treatment to achieve full remissions without increasing the risk of serious adverse effects.

The need to improve the quality of life of patients with IBD (especially of those who cannot be treated with biological drugs), makes it necessary for professionals to update their knowledge about the advantages and benefits of alternatives to these treatments currently available, so that they can be offered to the right patients.

Learning Objectives

Participating gastroenterologists will learn the role that GMA, either alone or combined, can actually play in the management of IBD. The course will also give them an overview, from the European perspective, of the mechanism of action, recent clinical history, data on the efficacy and practical aspects of using GMA in patients with IBD.

Course Outline

INTRODUCTION

Chairman: Dr. EUGENI DOMÈNECH

MODULE 1

Inflammatory bowel disease (IBD) Immunopatophysiology & immunolocical MoA of the Granulocytapheresis (GMA)

1.1. Granulocytapheresis (GMA): immunological effect over inflammation
Dr. RUBÉN FRANCÉS

MODULE 2

GMA immunological MoA: Clinical implications in UC treatment

2.1. Granulocyte-monocyte apheresis: scope of its effect in clinical practice
Dr. IAGO RODRIGUEZ-LAGO
2.2. Clinical implications in UC treatment – discussion
Chairman: Dr. EUGENI DOMÈNECH

MODULE 3

GMA immunological MoA: Physiological, immunological & clinical implications in UC treatment

3.1. Physiological and immunological implications of GMA Treatment in Ulcerative Colitis
Prof. GIORGOS BAMIAS
3.2. Real Clinical Experience with GMA use in IBD patients
Prof. GUILLAUME BOUGUEN
3.3. Physiological, immunological & clinical implications in UC treatment – discussion
Chairman: Dr. EUGENI DOMÈNECH

Authors

Dr. EUGENI DOMÈNECH
Gastroenterology Department.
Hospital Universitari Germans Trias i Pujol de Badalona.
Barcelona. Spain.

Dr. IAGO RODRIGUEZ-LAGO
Gastroenterology Department.
Hospital de Galdakao.
Vizcaya. Spain.

PROF. GUILLAUME BOUGUEN
Gastroenterology Department.
Hospital Rennes.
Rennes. France.

Dr. RUBÉN FRANCÉS
Clinical Medicine Department.
Immunology.
Hospital General Universitario de Alicante.
Alicante.Spain.

Prof. GIORGOS BAMIAS
Gastrointestinal Unit.
Sotiria Hospital.
Athens. Greece.